Growth factor

The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...


Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...


The European Commission ( EC ) has granted marketing authorization for Tukysa ( Tucatinib ) in combination with Trastuzumab and...


New data from the phase 1/2 trial of Mobocertinib orally administered in previously treated patients with epidermal growth factor receptor...



Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...


The European Commission has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of...


The European Commission ( EC ) has approved Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles...


The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...


Osimertinib ( Tagrisso ) is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation–positive advanced non–small-cell...


The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...


The FDA ( U.S. Food and Drug Administration ) has approved Tabrecta ( Capmatinib ) for the treatment of adult...


In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...


Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...


The European Commission has granted conditional marketing authorisation for Blenrep ( Belantamab mafodotin ) as monotherapy for the treatment of...


The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...